64Cu-SAR-bisPSMA (Clarity Pharmaceuticals): FDA status
Breakthrough designation Indication: PSMA PET imaging of prostate cancer in men with suspected biochemical recurrence based on elevated PSA. Company: Clarity Pharmaceuticals.
Regulatory history
- Nov 12, 2026: Breakthrough designation. FDA granted 64Cu-SAR-bisPSMA Breakthrough Therapy designation for PSMA PET imaging in men with suspected biochemical recurrence of prostate cancer, the first such designation in PSMA PET imaging. manilatimes.net
- Nov 27, 2024: Breakthrough designation. FDA granted fast track designation to 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer PET imaging. urologytimes.com
Loading today's edition…